A narrative review of antithrombin use during veno-venous extracorporeal membrane oxygenation in adults: rationale,current use,effects on anticoagulation,and outcomes
Restricted accessReview articleFirst published online September, 2020
A narrative review of antithrombin use during veno-venous extracorporeal membrane oxygenation in adults: rationale,current use,effects on anticoagulation,and outcomes
During extracorporeal membrane oxygenation, the large contact surface between the blood and the extracorporeal circuit causes a continuous activation of coagulation and inflammation. Unfractionated heparin, a glycosaminoglycan that must bind to antithrombin as a cofactor, is currently the standard anticoagulant adopted during extracorporeal membrane oxygenation. Antithrombin, beyond being a potent natural anticoagulant, acts in the cross-talk between coagulation and inflammatory system through anticoagulation and coagulation-independent effects.
Objectives:
In this review, we describe, in the adult setting of veno-venous extracorporeal membrane oxygenation, the pathophysiological rationale for antithrombin use, the current practice of administration, and the effects of antithrombin on anticoagulation, bleeding, and outcomes.
Data sources:
Studies on adults (18 years or older) on veno-venous extracorporeal membrane oxygenation published from 1995 to 2018 in order to evaluate the use of antithrombin.
Results:
In adults on veno-venous extracorporeal membrane oxygenation, antithrombin supplementation has a highly pathophysiological rationale since coagulation factor consumption, systemic inflammatory response syndrome, and endothelial activation are triggered by extracorporeal membrane oxygenation. Eleven articles are focused on the topic but among the authors there is no consensus on the threshold for supplementation (ranging from 70% to 80%) as well as on the dose (rarely standardized) and time of administration (bolus vs continuous infusion). Consistently, antithrombin is considered able to achieve better anticoagulation targets in or not in the presence of heparin resistance. The impact of antithrombin administration on bleeding still shows contrasting results.
Conclusion:
Antithrombin use in veno-venous extracorporeal membrane oxygenation should be investigated on the threshold for supplementation, dose, and time of administration.
EsperSAWelsbyIJSubramaniamK, et al. Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sang2017; 112: 443–452.
2.
CombesAHajageDCapellierG, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med2018; 378: 1965–1975.
3.
RaitenJMWongZZSpeldeA, et al. Anticoagulation and transfusion therapy in patients requiring extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth2017; 31: 1051–1059.
4.
LevyJHSniecinskiRMWelsbyIJ, et al. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost2016; 115: 712–728.
5.
OpalSMKesslerCMRoemischJ, et al. Antithrombin, heparin, and heparan sulfate. Crit Care Med2002; 30: S325–S331.
VayneCMayMABourguignonT, et al. Frequency and clinical impact of platelet factor 4-specific antibodies in patients undergoing extracorporeal membrane oxygenation. Thromb Haemost2019; 119: 1138–1146.
8.
CunninghamDBesserMWGiraudK, et al. Agreement between ACT and aPTT during extracorporeal membrane oxygenation shows intra- and inter-individual variation. Perfusion2016; 31: 503–507.
9.
KitchenSJenningsIWoodsTA, et al. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol1996; 49: 10–14.
10.
NewallF. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol2013; 992: 265–272.
11.
ArachchillageDRJKamaniFDeplanoS, et al. Should we abandon the APTT for monitoring unfractionated heparin?Thromb Res2017; 157: 157–161.
12.
SpiessBD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg2008; 85: 2153–2160.
13.
KawatsuSSasakiKSakatsumeK, et al. Predictors of heparin resistance before cardiovascular operations in adults. Ann Thorac Surg2018; 105: 1316–1321.
14.
MartucciGGrasselliGTanakaK, et al. Hemoglobin trigger and approach to red blood cell transfusions during veno-venous extracorporeal membrane oxygenation: the international TRAIN-ECMO survey. Perfusion2019; 34: 39–48.
15.
BembeaMMAnnichGRycusP, et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med2013; 14: e77–e84.
16.
DeatrickKBGalvagnoSMMazzeffiMA, et al. Pilot study evaluating a non-titrating, weight-based anticoagulation scheme for patients on veno-venous extracorporeal membrane oxygenation. Perfusion2020; 35: 13–18.
17.
LukitoPWongAJingJ, et al. Mechanical circulatory support is associated with loss of platelet receptors glycoprotein Ibα and glycoprotein VI. J Thromb Haemost2016; 14: 2253–2260.
18.
MazzeffiMStraussEMeyerM, et al. Coagulation factor levels and underlying thrombin generation patterns in adult extracorporeal membrane oxygenation patients. Anesth Analg2019; 129: 659–666.
19.
AbuelkasemEMazzeffiMAHendersonRA, et al. Clinical impact of protamine titration-based heparin neutralization in patients undergoing coronary bypass grafting surgery. J Cardiothorac Vasc Anesth2019; 33: 2153–2160.
20.
MorrisetteMJZomp-WiebeABidwellKL, et al. Antithrombin supplementation in adult patients receiving extracorporeal membrane oxygenation. Perfusion2020; 35: 66–72.
21.
MartucciGPanarelloGOcchipintiG, et al. Anticoagulation and transfusions management in veno-venous extracorporeal membrane oxygenation for acute respiratory distress syndrome: assessment of factors associated with transfusion requirements and mortality. J Intensive Care Med2019; 34: 630–639.
22.
IchiyamaMOhgaSOchiaiM, et al. Age-specific onset and distribution of the natural anticoagulant deficiency in pediatric thromboembolism. Pediatr Res2016; 79: 81–86.
23.
DowneyLFaraoniD. Antithrombin supplementation in infants undergoing cardiac surgery: a new piece of a complex puzzle. J Cardiothorac Vasc Anesth2019; 33: 403–405.
24.
ManlhiotCGruenwaldCEHoltbyHM, et al. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: impact of low antithrombin activity. J Thorac Cardiovasc Surg2016; 151: 444–450.
25.
SniecinskiRMChenEPTanakaKA. Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery. Blood Coagul Fibrinolysis2008; 19: 178–179.
26.
RyersonLMBruceAKLequierL, et al. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy. ASAIO J2014; 60: 559–563.
27.
NiimiKSFanningJJ. Initial experience with recombinant antithrombin to treat antithrombin deficiency in patients on extracorporeal membrane oxygenation. J Extra Corpor Technol2014; 46: 84–90.
28.
IapichinoGEProttiAAndreisDT, et al. Antithrombin during extracorporeal membrane oxygenation in adults: national survey and retrospective analysis. ASAIO J2019; 65: 257–263.
29.
MartucciGPanarelloGOcchipintiG, et al. Impact of cannula design on packed red blood cell transfusions: technical advancement to improve outcomes in extracorporeal membrane oxygenation. J Thorac Dis2018; 10: 5813–5821.
30.
DagerWEGosselinRCOwingsJT. Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: case report and review of the literature. Pharmacotherapy2004; 24: 659–663.
31.
KoppRMottaghyKKirschfinkM. Mechanism of complement activation during extracorporeal blood-biomaterial interaction: effects of heparin coated and uncoated surfaces. ASAIO J2002; 48: 598–605.
32.
MalfertheinerMVPhilippALubnowM, et al. Hemostatic changes during extracorporeal membrane oxygenation: a prospective randomized clinical trial comparing three different extracorporeal membrane oxygenation systems. Crit Care Med2016; 44: 747–754.
33.
MacielakSBurchamPWhitsonB, et al. Impact of anticoagulation strategy and agents on extracorporeal membrane oxygenation therapy. Perfusion2019; 34: 671–678.
34.
RaffiniL. Anticoagulation with VADs and ECMO: walking the tightrope. Hematology Am Soc Hematol Educ Program2017; 2017: 674–680.
35.
MurphyDAHockingsLEAndrewsRK, et al. Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev2015; 29: 90–101.
36.
MillarJEFanningJPMcDonaldCI, et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care2016; 20: 387.
37.
KiKKPassmoreMRChanCHH, et al. Effect of ex vivo extracorporeal membrane oxygenation flow dynamics on immune response. Perfusion2019; 34: 5–14.
38.
von BahrVMillarJEMalfertheinerMV, et al. Mesenchymal stem cells may ameliorate inflammation in an ex vivo model of extracorporeal membrane oxygenation. Perfusion2019; 34: 15–21.
39.
BromanLMPrahl WittbergLWestlundCJ, et al. Pressure and flow properties of cannulae for extracorporeal membrane oxygenation I: return (arterial) cannulae. Perfusion2019; 34: 58–64.
40.
BromanLMPrahl WittbergLWestlundCJ, et al. Pressure and flow properties of cannulae for extracorporeal membrane oxygenation II: drainage (venous) cannulae. Perfusion2019; 34: 65–73.
41.
MalfertheinerMVPimentaLPBahrVV, et al. Acquired von Willebrand syndrome in respiratory extracorporeal life support: a systematic review of the literature. Crit Care Resusc2017; 19: 45–52.
42.
TanakaKABharadwajSHasanS, et al. Elevated fibrinogen, von Willebrand factor, and Factor VIII confer resistance to dilutional coagulopathy and activated protein C in normal pregnant women. Br J Anaesth2019; 122: 751–759.
43.
Di NardoMVercaemstLSwolJ, et al. A narrative review of the technical standards for extracorporeal life support devices (pumps and oxygenators) in Europe. Perfusion2018; 33: 553–561.
44.
HoshinoKMuranishiKKawanoY, et al. Soluble fibrin is a useful marker for predicting extracorporeal membrane oxygenation circuit exchange because of circuit clots. J Artif Organs2018; 21: 196–200.
45.
KalbhennJWittauNSchmutzA, et al. Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy. Perfusion2015; 30: 675–682.
46.
FisserCReichenbacherCMullerT, et al. Incidence and risk factors for cannula-related venous thrombosis after venovenous extracorporeal membrane oxygenation in adult patients with acute respiratory failure. Crit Care Med2019; 47: e332–e339.
47.
Oude Lansink-HartgringAde VriesAJDrooghJM, et al. Hemorrhagic complications during extracorporeal membrane oxygenation—the role of anticoagulation and platelets. J Crit Care2019; 54: 239–243.
48.
TahamtanABaratiMTabarraeiA, et al. Antitumor immunity induced by genetic immunization with chitosan nanoparticle formulated adjuvanted for HPV-16 E7 DNA vaccine. Iran J Immunol2018; 15: 269–280.
49.
LapetinaEG. The signal transduction induced by thrombin in human platelets. FEBS Lett1990; 268: 400–404.
50.
NagallaSShawCKongX, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood2011; 117: 5189–5197.
51.
TeruelRCorralJPerez-AndreuV, et al. Potential role of miRNAs in developmental haemostasis. PLoS ONE2011; 6: e17648.
52.
Teruel-MontoyaRRosendaalFRMartinezC. MicroRNAs in hemostasis. J Thromb Haemost2015; 13: 170–181.
53.
SafdarHInoueYvan PuijveldeGH, et al. The role of hepatocyte nuclear factor 4α in regulating mouse hepatic anticoagulation and fibrinolysis gene transcript levels. J Thromb Haemost2010; 8: 2839–2841.
54.
SteffelJLuscherTFRuschitzkaF, et al. Cyclooxygenase-2 inhibition and coagulation. J Cardiovasc Pharmacol2006; 47: S15–S20.
55.
ZhengYLiuSQSunQ, et al. Plasma microRNAs levels are different between pulmonary and extrapulmonary ARDS patients: a clinical observational study. Ann Intensive Care2018; 8: 23.
56.
IsermannB. Homeostatic effects of coagulation protease-dependent signaling and protease activated receptors. J Thromb Haemost2017; 15: 1273–1284.
57.
TeruelRMartinez-MartinezIGuerreroJA, et al. Control of post-translational modifications in antithrombin during murine post-natal development by miR-200a. J Biomed Sci2013; 20: 29.
58.
NourseJBraunJLacknerK, et al. Large-scale identification of functional microRNA targeting reveals cooperative regulation of the hemostatic system. J Thromb Haemost2018; 16: 2233–2245.
59.
FortABorelCMigliavaccaE, et al. Regulation of fibrinogen production by microRNAs. Blood2010; 116: 2608–2615.
60.
MarchandAProustCMorangePE, et al. miR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS ONE2012; 7: e44532.
61.
JohnsonBFletcherSJMorganNV. Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan. Platelets2016; 27: 519–525.
62.
MeindersMKuluDIvan de WerkenHJ, et al. Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function. Blood2015; 125: 1957–1967.
63.
WajihNHutsonSMWallinR. siRNA silencing of calumenin enhances functional factor IX production. Blood2006; 108: 3757–3760.
PabstDBooneJBSoleimaniB, et al. Heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation and the role of a heparin-bonded circuit. Perfusion2019; 34: 584–589.
66.
PollakU. Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: review of the literature and alternative anticoagulants. J Thromb Haemost2019; 17: 1608–1622.
67.
SinJHLopezND. Argatroban for heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation with continuous venovenous hemofiltration. J Extra Corpor Technol2017; 49: 115–120.
68.
JyotiAMaheshwariADanielE, et al. Bivalirudin in venovenous extracorporeal membrane oxygenation. J Extra Corpor Technol2014; 46: 94–97.
69.
YoungGYonekawaKENakagawaP, et al. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion2004; 19: 283–288.
70.
NorthropMSSidonioRFPhillipsSE, et al. The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life. Pediatr Crit Care Med2015; 16: 66–74.
71.
WilliamsBMazzeffiMASanchezPG, et al. Case report of severe antithrombin deficiency during extracorporeal membrane oxygenation and therapeutic plasma exchange for double lung transplantation. A A Case Rep2017; 8: 11–13.
72.
DolchMEFreyLHatzR, et al. Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin-induced thrombocytopenia. Exp Clin Transplant2010; 8: 329–332.
73.
KimYSLeeHYangJH, et al. Use of argatroban for extracorporeal life support in patients with nonheparin-induced thrombocytopenia: analysis of 10 consecutive patients. Medicine2018; 97: e13235.
74.
LavandoskyGJ. A case of antithrombin replacement using recombinant human antithrombin in an adult patient supported with extracorporeal membrane oxygenation. Clin Case Rep2015; 3: 702–704.
75.
LorussoR. Extracorporeal life support and neurologic complications: still a long way to go. J Thorac Dis2017; 9: E954–E956.
76.
LorussoRTacconeFSBelliatoM, et al. Brain monitoring in adult and pediatric ECMO patients: the importance of early and late assessments. Minerva Anestesiol2017; 83: 1061–1074.
77.
LorussoRGelsominoSPariseO, et al. Neurologic injury in adults supported with veno-venous extracorporeal membrane oxygenation for respiratory failure: findings from the Extracorporeal Life Support Organization database. Crit Care Med2017; 45: 1389–1397.
78.
MartucciGLo ReVArcadipaneA. Neurological injuries and extracorporeal membrane oxygenation: the challenge of the new ECMO era. Neurol Sci2016; 37: 1133–1136.
79.
MartucciGReVLMarroneG, et al. Intracranial hemorrhage during extracorporeal membrane oxygenation: does family history play a role?Neurol Sci2015; 36: 1523–1525.
80.
MartucciGPanarelloGBertaniA, et al. Veno-venous ECMO in ARDS after post-traumatic pneumonectomy. Intensive Care Med2013; 39: 2235–2236.
81.
Di LorenzoGMartucciGSciaccaS, et al. Dysfunction of mechanical mitral prosthesis at 33rd week of pregnancy: ECMO support as a complex strategy for the mother and the fetus. Perfusion2016; 31: 611–613.
82.
Fletcher-SandersjööABartekJThelinEP, et al. Predictors of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation: an observational cohort study. J Intensive Care2017; 5: 27.
83.
AmiralJSeghatchianJ. Revisiting antithrombin in health and disease, congenital deficiencies and genetic variants, and laboratory studies on α and β forms. Transfus Apher Sci2018; 57: 291–297.
84.
RichardBSwansonRSchedin-WeissS, et al. Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin. J Biol Chem2008; 283: 14417–14429.
85.
MushunjeAEvansGBrennanSO, et al. Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost2004; 2: 2170–2177.
86.
HarperPLWilliamsonLParkG, et al. A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfus Med1991; 1: 121–128.
87.
AllingstrupMWetterslevJRavnFB, et al. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med2016; 42: 505–520.
88.
AllingstrupMWetterslevJRavnFB, et al. Antithrombin III for critically ill patients. Cochrane Database Syst Rev2016; 2: CD005370.
89.
PhillipsMRKhouryAIAshtonRF, et al. The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care2014; 42: 97–98.
90.
PieriMAgrachevaNBonaveglioE, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth2013; 27: 30–34.
